KATIE RUBIN: Open Payments
NPI 1013433978 · NEWARK, DE. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$410 in 22 payments from 11 companies in 2025. Trend: 2023 $0 · 2024 $266 · 2025 $410
Food & beverage: $410
| Company | Payments | Amount |
|---|---|---|
| Astellas Pharma US Inc | 6 | $110 |
| Amgen Inc. | 3 | $71 |
| Lilly USA, LLC | 2 | $40 |
| Sage Therapeutics, LLC | 2 | $37 |
| MILLICENT US INC | 2 | $34 |
| MAYNE PHARMA COMMERCIAL LLC | 2 | $26 |
| Novo Nordisk Inc | 1 | $23 |
| Bayer Healthcare Pharmaceuticals Inc. | 1 | $20 |
| Supernus Pharmaceuticals, Inc. | 1 | $18 |
| ABBVIE INC. | 1 | $16 |
Products named: Veozah, EVENITY, ZEPBOUND, ZURZUVAE, INTRAROSA, Wegovy, Mirena, Qelbree.
Industry payments across DE — which companies pay providers there.
